Last update 11 Dec 2024
EX-103
Last update 11 Dec 2024
Overview
Basic Info
Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms Anti-CD3/anti-CD20 bispecific T-cell engager, EX 103, EX103 |
Target |
Mechanism CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), CD3 stimulants(T cell surface glycoprotein CD3 stimulants) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with EX-103A Phase I/II Study Evaluating the Safety, Efficacy, and Pharmacokinetics of EX103 in Subjects With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
一项评价EX103注射液在复发或难治CD20阳性非霍奇金淋巴瘤患者中的有效性、安全性、耐受性和药代动力学特征的I/II期临床研究
[Translation] A Phase I/II clinical study to evaluate the efficacy, safety, tolerability and pharmacokinetic characteristics of EX103 injection in patients with relapsed or refractory CD20-positive non-Hodgkin's lymphoma
100 Clinical Results associated with EX-103
Login to view more data
100 Translational Medicine associated with EX-103
Login to view more data
100 Patents (Medical) associated with EX-103
Login to view more data
100 Deals associated with EX-103
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| CD20 positive Non-Hodgkin Lymphoma | Phase 2 | CN | 25 Oct 2021 | |
| Chronic Lymphocytic Leukemia | Phase 1 | US | 30 Jan 2022 | |
| Chronic Lymphocytic Leukemia | Phase 1 | CN | 30 Jan 2022 | |
| Non-Hodgkin Lymphoma | Phase 1 | US | 30 Jan 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1/2 | 23 | ztorqknxdu(poeesifslm) = All CRS events were grade (Gr) 1-2 (Gr 1: 78.3%, Gr 2: 13.0%), no Gr 3 or higher events dpqmaslqtg (nedrmzetrb ) View more | Positive | 24 May 2024 | |||
ESMO2023 Manual  | Phase 1 | 13 | csqjhkakdd(knhlrjqefv) = The most common adverse events were CRS and pyrexia, all were grade (Gr) 1-2, no Gr 3 or higher. Most CRS occurred in 1st or 2nd cycle, and resolved within 48 hours. No neurologic AE occurred. fuypdxgcpi (gvbkkmduuc ) | Positive | 23 Oct 2023 | ||
(DLBCL patients) |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free